Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

M.L.L. Prevoo, Martin A. van't Hof, H. H. Kuper et al. · Arthritis & Rheumatism · 1995 · 6.2K citations

Medicine, Clinical Sciences, Internal Medicine +15

Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis

Peter E. Lipsky, Désirée van der Heijde, E. William St. Clair et al. · New England Journal of Medicine · 2000 · 3K citations · Full text

Medicine, Immunology, Pharmacotherapy +14

Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

Ravinder N. Maini, E. William St. Clair, Ferdinand C. Breedveld et al. · The Lancet · 1999 · 2.4K citations

Medicine, Pharmacology, Pharmacotherapy +17

The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

Ferdinand C. Breedveld, Michael H. Weisman, Arthur F. Kavanaugh et al. · Arthritis & Rheumatism · 2005 · 1.8K citations

Medicine, Pharmacology, Pharmacotherapy +17

Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial

Michael E. Weinblatt, Edward Keystone, Daniel E. Furst et al. · Arthritis & Rheumatism · 2003 · 1.8K citations

Medicine, Pharmacology, Pharmacotherapy +15